Select a link below for details.
Study Detail: Alcon GAP
Trial Description
Summary : This is a natural history study being done to assess the rate of progression of geographic atrophy by measuring the growth of the atrophic lesions.
Basic Trial Information
|
Phase |
Disease |
Status |
Age |
Sponsor |
Protocol # |
|
NA |
Geographic Atrophy |
Enrolling |
55+ |
Alcon |
C-06-30 |
Study Duration: 18 months
Eligibility Criteria:
Inclusion Criteria
Primary study eye must have a contiguous well-demarcated area of GA larger than 2.5 mm² and less than or equal to 12 mm² (>1 to ≤ 5 DA). Best corrected vision in study eye is 20/100 or better.
Exclusion Criteria
Presence or history of CNV in either eye. Any ocular surgery within 90 days prior to the Baseline Visit. Current participation in other studies and previous or concomitant therapy to treat AMD. Other exclusion criteria per the study coordinatorGeneral Medical Exclusion Criteria
Any systemic disease with a limited survival prognosis (e.g., cancer, severe/unstable cardiovascular disease). Known medical history of allergy or sensitivity to fluorescein dye that is clinically relevant. Evidence of significant uncontrolled concomitant diseases such as cardiovascular, neurological, pulmonary, renal, hepatic, endocrine or gastrointestinal disorders. Other general inclusion/exclusion criteria per the study coordinator
Study Title : The Natural History of Geographic Atrophy Progression (GAP) Secondary to Age-Related Macular Degeneration (AMD)
Trial Contact Information
|
Site |
Study Coordinator |
|
Beachwood |
Vivian 216/831-5704 ext. 6800 |


